Spectrum pharmaceuticals and allos therapeutics announce extension of previously announced tender offer for shares of allos therapeutics
Allos Therapeutics, 05/11/2012
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. announced that, on May 2012, each had received from the Federal Trade Commission (FTC) a Request for Additional Information and Documentary Material (Second Request) under the Hart–Scott–Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Allos by Spectrum. Both parties are continuing to cooperate with the FTC.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.